Polatuzumab Vedotin in the Treatment of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma...
Diffuse large B-cell lymphoma (DLBCL), the most common type of an aggressive form of non-Hodgkin lymphoma (NHL) in the United States and worldwide, is...
Addressing the Challenges of Bioconjugate Medicines
Abstract
The continuing advancements in bioconjugate medicines from delivery of potent cytotoxins to vaccine-, oligonucleotide-, radionuclide-, immunomodulator- and check-point inhibitor-conjugates, can start to address the...
How the Next Generation Antibody Drug Conjugates Expands Beyond Cytotoxic Payloads for Cancer Therapy
Antibody-drug Conjugates or ADCs combine the selectivity of antibodies with the efficacy of small molecule drugs, allowing for more precise, targeted, therapeutic applications.
Combining the...
Modeling and Optimization of Antibody-drug Conjugate Production Using Process Intensified Solid-phase Method
Research article
Abstract
Conventional solution-phase method currently employed for the production of Antibody-drug Conjugates (ADC) has certain drawbacks, which makes production inefficient and cost extensive process....
Antibody-drug Conjugates with Novel Kinesin Spindle Protein Inhibitor Payloads and a Tailor-made Linker Chemistry
With the approval of meanwhile five ADCs and more than 80 ADCs in clinical trials, the ADC landscape has developed rapidly during the last...
Pharmacokinetic Considerations to Maximize an ADC’s Therapeutic Index
The Antibody-drug Conjugate (ADC) field is poised for several significant advances in solid tumors as the industry has built upon knowledge gained over the...
Confocal Microscopy and Imaging Flow Cytometry – Tools for Selection of Antibodies to be...
Research article
Abstract
Antibody-drug Conjugates (ADCs) are a growing class of targeted anti-cancer therapies, that combine the specific binding of an antibody with the toxic effects...
The Evolving Market for Antibody-drug Conjugates
The scale of patient demand has fueled an overarching healthcare market need to expand the drug development pipeline to generate more biologics to treat...
Emerging Trends in Single-Use Technology in the Manufacturing of Antibody-Drug Conjugates
Single-use technology, designed for the manufacturing of biopharmaceutical products, has made major inroads over the last 30 years. First introduced in the late 1970s...
Four Ways to Show Nonobviousness of ADC Inventions
As research continues to progress and the scientific community’s appreciation for the power of ADCs has grown, so have the numbers. FDA has now approved at least four ADCs, and hundreds more are in development. The number of patent applications has also grown, with the U.S. Patent and Trademark Office (USPTO) publishing over two hundred patent applications with claims to ADC inventions in the last two years alone.
